Publications (155) Rocío Isabel Rodríguez Macías publications

filter_list

2025

  1. Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma

    Cancers

  2. Mapping the landscape of biliary tract cancer in Europe: challenges and controversies

    The Lancet Regional Health - Europe, Vol. 50

  3. New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe

    The Lancet Regional Health - Europe, Vol. 50

  4. Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk

    Hepatology

  5. The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance

    American Journal of Pathology, Vol. 195, Núm. 3, pp. 422-436

2024

  1. Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease

    Annals of Surgical Oncology, Vol. 31, Núm. 10, pp. 6495-6503

  2. Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition

    Biochemical Pharmacology, Vol. 228

  3. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

  4. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3

    Biomedicine and Pharmacotherapy, Vol. 180

  5. Strategies to enhance the response of liver cancer to pharmacological treatments

    American journal of physiology. Cell physiology, Vol. 327, Núm. 1, pp. C11-C33

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  3. Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

    Cells, Vol. 12, Núm. 8

  4. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis

    Cells, Vol. 12, Núm. 16

  5. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

  6. Mitochondrial RNA methyltransferase TRMT61B is a new, potential biomarker and therapeutic target for highly aneuploid cancers

    Cell Death and Differentiation, Vol. 30, Núm. 1, pp. 37-53

  7. Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma

    Biochemical Pharmacology, Vol. 214

  8. Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy

    Cancers, Vol. 15, Núm. 12

  9. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

  10. Serum lipidome unravels a diagnostic potential in bile acid diarrhoea

    Gut, Vol. 72, Núm. 9, pp. 1698-1708